Compounds > olmesartan
Page last updated: 2024-09-04

olmesartan and zolpidem

olmesartan has been researched along with zolpidem in 4 studies

Compound Research Comparison

Studies
(olmesartan)		Trials
(olmesartan)		Recent Studies (post-2010)
(olmesartan)		Studies
(zolpidem)		Trials
(zolpidem)		Recent Studies (post-2010) (zolpidem)
8411855541,825368683

Protein Interaction Comparison

ProteinTaxonomyolmesartan (IC50)zolpidem (IC50)
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)0.048
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)0.048
Translocator proteinRattus norvegicus (Norway rat)4.7
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)0.048
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)0.048
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)0.048
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)0.048
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)0.048
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)0.048
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)0.048
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)0.048
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)0.048
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)0.048
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)0.048
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)0.048
GABA theta subunitRattus norvegicus (Norway rat)0.048
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)0.048

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's3 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Andricopulo, AD; Moda, TL; Montanari, CA1
Ekins, S; Williams, AJ; Xu, JJ1
Fukami, T; Hosomi, H; Iwamura, A; Nakajima, M; Yokoi, T1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY1

Other Studies

4 other study(ies) available for olmesartan and zolpidem

ArticleYear
Hologram QSAR model for the prediction of human oral bioavailability.
    Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

    Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2007
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
    Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:5

    Topics: Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Benzbromarone; Biotransformation; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C9; Diclofenac; HEK293 Cells; Hep G2 Cells; Hepatocytes; Humans; Losartan; NF-E2-Related Factor 2; Semicarbazides; Sensitivity and Specificity; Time Factors; Uricosuric Agents

2011
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding

2012